Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection

Next Previous
Search
Trial Profile

A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glecaprevir/pibrentasvir (Primary) ; Daclatasvir; Sofosbuvir
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms ENDURANCE 3
  • Sponsors AbbVie

    • Most Recent Events

    • 28 Mar 2019 Results assessing the efficacy and safety of Glecaprevir/Pibrentasvir treatment for 8-16 weeks from 9 Phase II and Phase III trials (NCT02243280, NCT02243293, NCT02604017, NCT02640482, NCT02640157, NCT02636595, NCT02642432, NCT02651194, and NCT02446717) published in the Clinical Infectious Diseases.
    • 01 Dec 2018 Results of a pooled post-hoc analysis from ENDURANCE-1, 2, 3, 4, 5 studies, published in the Infectious Diseases and Therapy
    • 30 Jul 2018 Results of pooled data from 8 studies (SURVEYOR-1, 2, ENDURANCE-1, 2, 3, 4, and EXPEDITION-1, 4), were published in the Antimicrobial Agents and Chemotherapy.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top